Mitchell S. V. Elkind, M.D., M.S., FAAN, FAHA


Mitchell S. V.  Elkind, M.D., M.S., FAAN, FAHA

Mitchell Elkind, MD, MS is a tenured Professor of Neurology and Epidemiology at Columbia University, and Chief of the Division of Neurology Clinical Outcomes Research and Population Sciences in the Neurology Department.

Dr Elkind’s research focuses on stroke prevention, inflammatory and infectious biomarkers in stroke risk prediction, atrial cardiopathy, immune therapy for acute stroke, and vascular causes of cognitive aging. He is a principal investigator of federally-funded studies examining atrial cardiopathy in cryptogenic stroke; stroke risk factors; short-term high-dose statin therapy in acute stroke; and inflammation in stroke treatment.

Dr. Elkind has a longstanding commitment to medical education and research training. In addition to leading the Columbia Neurology residency and fellowship programs, he serves as editor of the AHA/ASA Stroke journal’s new International Stroke Early Career and Training Section. He also runs National Institutes of Health-funded research training programs for residents and fellows.

Dr. Elkind has served on several AHA/ASA committees, including three terms on the National Board of Directors (2014-2020), two terms as chair of the ASA Advisory Committee (2016-2020), and co-chair or member of several writing committees for guidelines and scientific statements. He co-chaired the writing committee for the 2012 scientific statement on the inclusion of stroke as an outcome and risk equivalent in vascular disease risk scores, and currently serves as co-chair of the stroke section of the annual statistical update.